{
  "data": {
    "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGDF",
    "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDF",
    "indicator": {
      "slug": "pharmaceuticals-division-sales-growth-in-swiss-francs",
      "name": "Pharmaceuticals division sales growth in Swiss francs",
      "definition": "Percentage change in pharmaceuticals division sales reported in Swiss francs over the specified period."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "period": {
      "start": "2026-01-01",
      "end": "2026-06-30",
      "type": "quarter"
    },
    "value": -1,
    "value_text": "-1%",
    "unit": "percent",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "Roche",
      "org_short_name": "Roche",
      "org_url": "https://www.roche.com",
      "org_tier": 2,
      "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...",
      "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23",
      "document_type": "press_release",
      "locator": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc",
      "quote": "Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales of our medicines across disease areas; Xolair (allergic asthma, chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers.",
      "published_date": "2026-07-23",
      "accessed_at": "2026-09-15",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-15T22:15:46.809Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDF",
      "bibtex": "@misc{roche2026pharmaceuticalsbjmgdf,\n  author       = {{Roche}},\n  title        = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDF},\n  note         = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}"
    },
    "updated_at": "2026-09-15T22:15:46.809Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}